Facilitated, small-group discussions. Interactive participation leads to problem-solving solutions and future collaborations around focused topics.
What's the BuzZ about?
PepTalk’s BuzZ Sessions are focused, stimulating discussions in which delegates discuss important and interesting topics related to upstream protein expression and production through downstream scale-up and manufacturing. This is a moderated discussion with brainstorming and interactive problem-solving between scientists from diverse areas who share a common interest in the discussion topic.
These are forums for open discussion of protein-related challenges, and not sales opportunities. We emphasize that these breakout groups are for interactive discussions among scientists and are not meant to be, in any way, a corporate or product discussion. Topics can be limited to one protein area or may address issues which cross over the borders between pipeline meeting topics. Moderators should be well-versed in the topic area and able to keep the discussion focused and productive.
Due to popular demand, we’ll host two BuzZ Session times this year. All BuzZ Sessions will be located in the Convention Center Lobby on Tuesday, January 14. Session A will be held 2:00-3:00 pm and Session B 3:45-4:45 pm.
To submit a BuzZ Session topic for consideration, please click here.
Current Discussion Table Topics
Personalizing PepTalk: An Introduction to our Event App
Deborah Shear, Associate Director, Production, Cambridge Healthtech Institute
Cross-Reactive Neutralizing Monoclonal Antibodies (mAbs)
Dimiter S. Dimitrov, Ph.D., Senior Investigator, Protein Interactions Group, National Cancer Institute, NIH
Bispecific Antibodies vs. Oligoclonal Antibodies
Greg Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center
Functional Mapping and Directed Evolution of Protein Interactions using Combinatorial Libraries and Extensive Mutagenesis
Gertrudis Rojas, Ph.D., Group Leader, Protein Engineering, Systems Biology, Center of Molecular Immunology
Exploring the Use of Purified Membrane Proteins as Antigens for mAb Development
Jian Payandeh, Ph.D., Scientist, Structural Biology, Genentech, Inc.
The Role of Deep Sequencing in Affinity Reagent Selections
Csaba Kiss, Ph.D., Team Leader, Bioscience Division, Los Alamos National Laboratory
The Role of Fc Receptors in Immunomodulatory mAb Function
Ann White, Ph.D., Senior Research Fellow, University of Southampton, United Kingdom
Changes in Patent Law: Obtaining Meaningful Protection for Your Invention
John L. Marquardt, Jr., J.D., MBA, Ph.D., Attorney at Law, Marquardt Law
Translation Strategies to Develop Next-Generation mAbs
Randall Brezski, Ph.D., Senior Scientist, Biotechnology Center of Excellence, Janssen R&D
Next Generation of Antibodies - Bispecific vs. Mixtures
Ivan Horak, M.D., CSO and CMO, Symphogen
Preclinical Pharmaceutical Target Validation: Is it Possible?
James W. Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Velocity Pharmaceutical Development
Antibody Combinations in Discovery and Development
David Buckler, Ph.D., Director, Therapeutic Proteins, Regeneron Pharmaceuticals
Half-Life Extension of Biopharmaceuticals
Volker Schellenberger, Ph.D., CEO and President, Amunix
Solving Manufacturing Issues with (Fusion) Proteins
Stefan Schmidt, Ph.D., Vice President, DSP, Rentschler Biotechnology
Mass Spectrometric Techniques for Protein Therapeutic Analysis
Jennifer Nemeth, Ph.D., Principal Research Scientist and Head, Biologics Mass Spectrometry & Allied Technologies, Janssen R&D LLC
Advantages of Site-Specific Antibody Drug Conjugation Technologies
Aaron K. Sato, Ph.D, Vice President, Research, Sutro Biopharma
Clinical Aspects of ADCs
Robert S. Kahn, M.D., CPI, Safety Science Leader, Early Clinical Development, Global Safety Risk Management, Genentech, Inc.
High-Throughput Stress and Characterization Techniques
Vladimir Razinkov, Ph.D., Principal Scientist, Amgen
Predicting Pharmaceutical Stability from Accelerated Stress Studies and Measurements of Protein Conformational Stability
Mark Brader, Ph.D., Principal Scientist, Biogen Idec
QbD: Where are We in Drug Product Development?
Steven LaBrenz, Ph.D., Scientific Director, Drug Product Development, Janssen R&D
High-Throughput Formulation Screening in Early Process Development
Nicolas Moniotte, Ph.D., Technology Development Leader, R&D Formulation Development, GlaxoSmithKline Vaccines
Particulate Formation in Protein Drug Products
Meera Agarkhed, Principal Associate, Formulation Development, ImClone Systems, a Wholly-Owned Subsidiary of Eli Lilly & Co.
Kinetics and Thermodynamics Controls of Protein Aggregation
Murali Bilikallahalli, Ph.D., Associate Director, Formulation Sciences, Proteins, Vaccines & Oligos, MedImmune
Implications of Controlled Ice Nucleation in Freeze-Drying
Vamsi Mudhivarthi, Ph.D., Postdoctoral Fellow, Pharmaceutical Sciences, University of Connecticut
Improving Protein Solubility
Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
Solid State Protein Stabilization through Formulation and Non-Lyo-Based Process Strategies
Jeffrey Breit, Ph.D., Director, Pharmaceutical, Bend Research
Reconstitution of High-Concentration Freeze-Dried Proteins
Bakul Bhatnagar, Ph.D., Principal Scientist, BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc.
High Volume/Viscosity Subcutaneous Drug Delivery - Challenges and Opportunities
Michael D. Hooven, President and CEO, Enable Injections, LLC
Design on Experiments in Biologics Drug Product Development
Vishal C. Nashine, Ph. D., Senior Research Investigator, Bristol-Myers Squibb
Confinement of Biologics in Nanopores: Mimicking Nature or Improving Upon Nature for Enhanced Stability, Delivery and Activity?
Pankaj Karande, Ph.D., Assistant Professor, Department of Chemical & Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute
Lift Off: Integrated Launch of a New Biotech Company, from Technology to Team to Launch to Exit Plan
Joseph Kittle, Jr., Ph.D., Assistant Professor, Chemistry and Biochemistry, Ohio University and CSO, Molecular Technologies Laboratories, LLC
Lawrence J. Tartaglia, Ph.D., Researcsh Scientist, Biochemistry and Molecular Biology, Center for Structural Biology, University of Florida
What More Can Be Done for Downstream?
Wei Chen, Ph.D., Managing Director, BioPharmaneer, Inc.
Analytical Method Development in Support of Process Development and Manufacture
Chaminda Salgado, Head, CMC Bioassay and Genomics, CMC Bioassay and Genomics, NDA-Analytics
Protein Complexes and Multi-Gene Constructs Generation
Wassim Abdulrahman, Ph.D., Research Scientist, Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research and CPC Novartis
Monoclonal Antibodies that Selectively Detect Nerve Agent Biomarkers
John Cashman, Ph.D., President and Founder, Human BioMolecular Research Institute
Common Issues with Transient Protein Production
Richard Altman, MS, Research Scientist, Alexion Pharmaceuticals
Henry C. Chiou, Ph.D., Senior Product Manager, Life Technologies
Krista Johnson, MSc, Research Scientist, Alexion Pharmaceuticals
Next-Generation Expression Platforms
Miller Tran, Ph.D., Senior Scientist, Triton Algae Innovations
Expression and Affinity Tags for Production of Recombinant Proteins
Alexei Yeliseev, Ph.D., Staff Scientist, Protein Biochemistry, LMBB, National Institutes of Health
How to Control Product Quality without Sacrificing Productivity
Zhimei Du, Ph.D., Senior Scientist, Cell Sciences & Technology, Amgen, Inc.
Increasing Transient Expression Titers
Bernie Sweeney, Ph.D., Senior Group Leader, Mammalian Expression, UCB
Managing Your “Crown Jewels”: Internally Produced Protein-Related Information
Peter Nollert, Ph.D., Vice President, Technology and Client Solutions and Head, Membrane Protein Practice, Emerald Bio
Tricks of the Trade: From Protein Purification to X-Ray Crystallography
Vinodh Kurella, Ph.D., Research Fellow, Bioinformatics, Harvard Medical School
Using Mammalian Expression Systems to Express Drug Targets
Jiansheng Wu, Ph.D., Scientist, Protein Chemistry, Genentech, Inc.
Advances in Protein Purification by Chromatography and Market Adaptation
Yamuna Dasarathy, Ph.D., MBA, Director, Marketing, Chromatography, Pall Life Sciences
Continuous Chromatography for Protein Purification
Andrew L. Zydney, Ph.D., Department Head and Walter L. Robb Family Chair, Chemical Engineering, The Pennsylvania State University
Protein Melting as a Tool for Buffer Optimization and Protein Characterization Discussion Points
Bill Gillette, Ph.D., Senior Scientist, Group Leader, Protein Purification, Protein Expression Laboratory, Advanced Technology Program SAIC-Frederick, Inc.
Where is Downstream Processing Headed? - Pre-Packed Columns, Continuous Processing, Alternatives to Protein A, Filtration and the Next Steps
Adam Goldstein, MSc, Principal Engineer, Genentech, Inc.
Bringing Single-Use to Fill/Finish
Jessica Frantz, Field Marketing Manager, Aseptic Transfer Systems, Fluid Management Technologies, Sartorius Stedim Biotech North America
Risk Assessment and Control Strategies for Extractables & Leachables
Ken Wong, Center for Extractables and Leachables (CEL), ACDS – Specialty Analytical & Informatics (SAI), Merck & Co.
Vendor Qualification, Supplier Agreement and Establishing Quality Standards for Single-Use Implementation
Morten Munk, Vice President, Business Development, Technology Specialist, CMC Biologics
Optimizing Continuous Downstream Processing
SeongKyu Yoon, Ph.D., Assistant Professor & Director, Department of Chemical Engineering, Massachusetts Bio Manufacturing Center, University of Massachusetts
Single-Use Supply Chain Risk
Leslie Cianella, EMBA, CPIM, CQA, Senior Sourcing and Procurement Manager, Supply Chain Operations, MedImmune, Inc.
The Future of Biomanufacturing: Flexible, Compact, Cost-Effective and Modular Facilities
Sadettin S. Ozturk, Ph.D., Head, Process and Analytical Development, MassBiologics
Open Ballroom Manufacturing – Will It Be Accepted by the Industry and Regulators?
John Knighton, MBA, Senior Director, API Large Molecule Technologies & Alliances, Janssen R&D
Regulatory Considerations for Multiproduct Facilities
John Godshalk, Senior Consultant, GMP, CMC, Biologics Consulting Group, Inc. and former Review/Inspector, Division of Manufacturing and Product Quality, CBER, U.S. FDA
Enabling "Biotech on Demand" and "Best of Breed" Biopharmaceutical Process Development and Manufacturing
Robert F. Dream, PE, Principal, HDR Company LLC
Technologies and Process Integration in Modular Facilities
Par Almhem, President, ModWave
Label-Free Assays in Biotherapeutic Discovery and Development – The Right Tools for the Right Job
Vishal Kamat, Ph.D., Scientist, Biomolecular HTS Center, Therapeutic Proteins, Regeneron Pharmaceuticals
Site-Specific Modification of Proteins in Display Platforms
Carrie Marshall, Research Assistant, Chemical & Biological Engineering, College of Engineering, University of Wisconsin Madison
Protein Sequences and Structural Elements of Therapeutic Antibodies Modulating Protein Production Levels in Mammalian Cells
Xiaotian Zhong, Ph.D., Principal Scientist & Lab Head, GBT, Pfizer Global BioTherapeutic R&D
Production Challenges for Fc-Fusion Proteins
Steven Chamow, Ph.D., Principal Consultant, Chamow & Associates, Inc.
Post-Formulation Stability Studies: Intracellular Stress Pathways in Antibody-Producing CHO Cells
Stephanie A. Davies, Postgraduate Research Student, Biosciences, the University of Kent
Challenges in High-Throughput Generation and Characterization of Antibody Candidates
Sebastian Schlicker, Project Manager, Biologics, Genedata USA Inc.
Challenges in Conjugation and Characterization of ADCs
Samadhi Vitharana, Ph.D., Senior Scientist, Core Sciences & Technology, Takeda
Epitope Binning & Its Importance
Benjamin Brooks, Ph.D., VP, R&D, Wasatch Microfluidics
Can Antibodies with Exquisite Specificity and High Affinity Binding to an Antigen be Developed from Synthetic Antibody Libraries?
An-Suei Yang, Ph.D., Research Fellow, Genomics Research Center, Academia Sinica
Protein Purification and Recovery Technology- What’s New or Worth Exploring, and What’s Causing More Challenges than Benefits ?
Yan-ping Yang, Ph.D., Director, Downstream Purification, Bioprocess Research & Development, sanofi pasteur
Expression of Recombinant Kinases
Alexei Degterev, Ph.D., Associate Professor, Tufts University
Challenges and Opportunities in Membrane Protein Research
Qinghai Zhang, Ph.D., Associate Professor, Integral Structural and Computational Biology, The Scripps Research Institute
Solving the Problems of Protein Expression
Andrew Fosberry, Ph.D., Manager, Expression & Fermentation Sciences, Biological Reagents and Assay Development, PTS, GlaxoSmithKline Research & Development Limited
Strategies to Tackle Difficult Preparative Protein Purification Challenges
Thomas Müller-Späth, Ph.D., CSO, ChromaCon AG
Andrew Stephen, Ph.D., Acting Director, Protein Chemistry Laboratory, Frederick National Laboratory for Cancer Research, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research
Techniques for Large-Scale Purification of Recombinant Proteins
Ellen Brune, Ph.D., CSO, Boston Mountain Biotech
Challenges and Opportunities in Continuous and Single-Use Downstream Processing of Pharmaceutical Proteins
Boris Napadensky, VP, Engineering, Chromatan Corporation
Challenges and Solutions for Non-Platform Molecules
Georg Blaser, Ph.D., Group Leader, Applied Protein Services, Lonza Biologics